GlassScriptPhysician profile
Sherry L Smith
NPI 1740513308
$326.00
in general payments reported to CMS, 2019-2025
15 companies · $14.36 in 2025
The $14.36 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.60 · 2022: $54.08 · 2023: $98.28 · 2024: $146 · 2025: $14.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $258.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $80.44 | 2022-2024 | Keytruda |
| Adc Therapeutics America, INC. | $36.55 | 2023-2024 | |
| Amgen INC. | $20.83 | 2023 | Lumakras |
| Takeda Pharmaceuticals U.S.A., INC. | $20.45 | 2024 | Ninlaro |
| Array Biopharma INC | $18.00 | 2024 | Mektovi, Lorbrena, Braftovi |
| Incyte Corporation | $18.00 | 2024 | Jakafi |
| Pfizer INC. | $18.00 | 2024 | |
| Seagen INC. | $16.00 | 2023 | Adcetris |
| Pharmaessentia USA Corporation | $15.61 | 2024 | Besremi |
| Ironwood Pharmaceuticals, INC | $14.74 | 2023 | Linzess |
| Genzyme Corporation | $14.46 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $14.36 | 2025 | Enhertu |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.60 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.00 | 2023 | |
| Gilead Sciences, INC. | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.